IR@PKUHSC  > 北京大学药学院
学科主题药学
The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer
Zhou, Jia1; Zhao, Wei-Yu1; Ma, Xu1; Ju, Rui-Jun1; Li, Xiu-Ying1; Li, Nan1; Sun, Meng-Ge1; Shi, Ji-Feng1; Zhang, Cheng-Xiang1; Lu, Wan-Liang1,2
关键词TPGS(1000)-TPP conjugate Targeting paclitaxel liposomes Mitochondrial signaling pathway Resistant lung cancer Anticancer efficacy
刊名BIOMATERIALS
2013-05-01
DOI10.1016/j.biomaterials.2013.01.078
34期:14页:3626-3638
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Engineering, Biomedical ; Materials Science, Biomaterials
研究领域[WOS]Engineering ; Materials Science
关键词[WOS]VITAMIN-E-TPGS ; HUMAN NEUROBLASTOMA-CELLS ; CYTOCHROME-C RELEASE ; POLYETHYLENE-GLYCOL ; IN-VITRO ; DRUG-DELIVERY ; APOPTOSIS ; NANOPARTICLES ; CYTOTOXICITY ; MECHANISM
英文摘要

Lung cancer is the leading cause of cancer-related death in humans and the multidrug resistance (MDR) is the major obstacle to successful chemotherapy of lung cancer. In this study, a D-alpha-tocopheryl polyethylene glycol 1000 succinate-triphenylphosphine conjugate (TPGS(1000)-TPP) was synthesized as the mitochondrial targeting molecule, and was incorporated onto the surface of paclitaxel liposomes to treat the drug-resistant lung cancer. Evaluations were performed on the human lung cancer A549 cells, the drug-resistant lung cancer A549/cDDP cells, and the drug-resistant lung cancer A549/cDDP cells xenografted nude mice. The yield of TPGS(1000)-TPP conjugate synthesized was about 50% and the particle size of targeting paclitaxel liposomes developed was approximately 80 nm. In comparison with taxol and regular paclitaxel liposomes, the targeting paclitaxel liposomes exhibited the strongest anticancer efficacy in vitro and in the drug-resistant A549/cDDP xenografted tumor model. The targeting paclitaxel liposomes could significantly enhance the cellular uptake, be selectively accumulated into the mitochondria, and cause the release of cytochrome C. This targeting delivery of drug initiated a cascade of caspase 9 and 3 reactions, activated the pro-apoptotic Bax and Bid proteins and suppressed the antiapoptotic Bcl-2 protein, thereby enhancing the apoptosis by acting on the mitochondrial signaling pathways. In conclusion, the targeting paclitaxel liposomes have the potential to treat drug-resistant lung cancer. (C) 2013 Elsevier Ltd. All rights reserved.

语种英语
WOS记录号WOS:000317534200009
项目编号2013CB932501 ; 81172991 ; BMU20110263
资助机构National Basic Research Program of China (973 program) ; Grant of National Science Foundation of China ; State Key Laboratory of Drug Delivery Technology and Pharmacokinetics (Tianjin Institute of Pharmaceutical Research) ; Grant for Innovation Team of Ministry of Education
引用统计
被引频次:81[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/61394
专题北京大学药学院
医学人文研究院/公共教学部_哲学与社会科学系
北京大学第一临床医学院_检验科
作者单位1.Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing 100191, Peoples R China
2.Tianjin Inst Pharmaceut Res, State Key Lab Drug Delivery Technol & Pharmacokin, Tianjin 300193, Peoples R China
推荐引用方式
GB/T 7714
Zhou, Jia,Zhao, Wei-Yu,Ma, Xu,et al. The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer[J]. BIOMATERIALS,2013,34(14):3626-3638.
APA Zhou, Jia.,Zhao, Wei-Yu.,Ma, Xu.,Ju, Rui-Jun.,Li, Xiu-Ying.,...&Lu, Wan-Liang.(2013).The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer.BIOMATERIALS,34(14),3626-3638.
MLA Zhou, Jia,et al."The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer".BIOMATERIALS 34.14(2013):3626-3638.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zhou, Jia]的文章
[Zhao, Wei-Yu]的文章
[Ma, Xu]的文章
百度学术
百度学术中相似的文章
[Zhou, Jia]的文章
[Zhao, Wei-Yu]的文章
[Ma, Xu]的文章
必应学术
必应学术中相似的文章
[Zhou, Jia]的文章
[Zhao, Wei-Yu]的文章
[Ma, Xu]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。